Drug Trial Radar · NCT06567470
A Study With CIT-013 in RA Patients
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
96
Actual
Start
Jul 29, 2025
Primary completion
Jul 2, 2026
Study completion Aug 11, 2026
Sponsor
- Lead sponsor
- Citryll BVIndustry
- Sponsor type
- Industry
- First posted
- Aug 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if CIT-013 works to treat rheumatoid arthritis in adults. It will also learn about the safety of CIT-013. The main questions it aims to answer are: Does CIT-013 lower the disease activity of RA patients? What medical problems do participants have when receiving CIT-013? Researchers will compare CIT-013 to a placebo (a look-alike substance that contains no drug) to see if CIT-013 works to treat the symptoms of RA. Participants will: Take receive CIT-013 or placebo every other week for 6 weeks and 50 mg CIT-013 for 6 weeks Visit the clinic once every 2 weeks for checkups and tests Keep monitor their symptoms during this period
Conditions
- Rheumatoid Arthritis
Interventions
CIT-013 low doseDrug
Subcutaneous injection
CIT-013 high doseDrug
Subcutaneous injection
PlaceboDrug
Subcutaneous injection
CIT-013 medium doseDrug
CIT-013 medium dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- The change in DAS28-CRP at week 6 compared to baselineTime frame: week 6
Locations
20 sites in 5 countries. Site status is shown where the registry gives one.
Site BE-01
Leuven, Belgium
DE-04
Bamberg, Germany
DE-05
Berlin, Germany
DE-01
München, Germany
DE-02
München, Germany
NL-05
Leeuwarden, Netherlands
NL-03
Nijmegen, Netherlands
NL-01
Rotterdam, Netherlands
PL-01
Bialystok, Poland
PL-07
Krakow, Poland
PL-03
Lublin, Poland
PL-02
Poznan, Poland
PL-05
Torun, Poland
PL-04
Warsaw, Poland
ES-02
A Coruña, Spain
ES-04
Barcelona, Spain
ES-05
Barcelona, Spain
ES-06
Madrid, Spain
ES-01
Santander, Spain
ES-03
Santiago de Compostela, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.